Kuano

Kuano is an artificial intelligence company using quantum computing to create molecular design solutions that is headquartered in London, England and was founded in 2020 by Vid Stojevic, David Wright, Parminder Ruprah, and Jarryl D'Oyley.

Kuano focuses on developing enzyme inhibitors using artificial intelligence and quantum computing simulations for pharmaceutical, crop protection, and industrial chemistry applications. Properties of enzyme inhibitors being selected for by Kuano include enzyme binding transition states, enzyme transition state selectivity, and ability to maintain enzyme function regardless of possible mutations. Kuano manipulates enzyme properties to create enzyme inhibitors with more desirable dosage levels, toxicity levels, and resistance levels to mutations.

Kuano has developed a computer assisted drug design (CADD) and other molecule design workflows called the Nautilus platform. The company allows the Nautilus platform to be licensed out to support other projects in need of quantum simulation and artificial intelligence related to drug design, or the company will work directly with other companies on projects to help with the molecular design process.

Examples of pilot projects worked on by Kuano include: designing transition state inhibitors for target enzymes, discovery requirements for resistance repair for specific compounds and classes of compounds, enzyme inhibition predictions, identifying distinct chemotypes, and expanding knowledge of a chemotype and the creation of a soft focus screening library.